Skip to content
X-twitter Linkedin Youtube
  • FR
  • EN
  • FR
  • EN
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact
Menu
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact

Day: July 10, 2024

End of the liquidity contract with GILBERT DUPONT

GeNeuro SA and GILBERT DUPONT have terminated the liquidity contract entered into on March 6, 2021. This termination took effect on June 30, 2024, after market closing

© 2025 GeNeuro SA

  • Legal Notice

 3, Chemin du Pré-Fleuri
CH-1228 Plan-les-Ouates
Geneva, Switzerland

  • contact@geneuro.com
X-twitter Linkedin Youtube